Avalo Therapeutics (AVTX) Net Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly Net Margin came in at 23254.24% in Q4 2025, down 484851.0% YoY from N/an in Q4 2024, and down 26.34% on a QoQ basis from 18405.73% in Q4 2024.
Avalo Therapeutics (AVTX) Net Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 9 years of Net Margin data on file, last reported at 23254.24% in Q4 2025.
- Quarterly Net Margin fell 484851.0% year-over-year to 23254.24% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15651.8% (down 768604.0% YoY) and the FY2025 annual result came in at 132642.37%, down 12467661.0% from the prior year.
- Net Margin declined to 23254.24% in Q4 2025, from 18405.73% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 9251.81% in Q3 2024 to a low of 23254.24% in Q4 2025.
- A 4-year average of 3588.02% and a median of 1274.18% in 2023 frame the typical range for Net Margin.
- The widest YoY moves for Net Margin: up 1146706 bps in 2024, down 1697526 bps in 2024.
- Tracing AVTX's Net Margin over 4 years: stood at 29.68% in 2021, then sank by 4720 bps to 1430.47% in 2023, then slumped by 1187 bps to 18405.73% in 2024, then fell by 26 bps to 23254.24% in 2025.
- The last three Net Margin figures came in at 23254.24% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,254.24% |
| Dec 31, 2024 | -18,405.73% |
| Sep 30, 2024 | 9,251.81% |
| Dec 31, 2023 | -1,430.47% |
| Sep 30, 2023 | -2,215.25% |
| Jun 30, 2023 | -1,274.18% |
| Mar 31, 2023 | -2,095.79% |
| Dec 31, 2021 | -29.68% |
| Sep 30, 2021 | 5.63% |
| Jun 30, 2021 | 2.06% |
| Mar 31, 2021 | -22.41% |
| Dec 31, 2020 | 33.33% |
| Sep 30, 2020 | -17.82% |
| Jun 30, 2020 | -34.01% |
| Mar 31, 2020 | 37.69% |
| Dec 31, 2019 | 183.28% |
| Sep 30, 2019 | -49.33% |
| Jun 30, 2019 | -262.78% |
| Mar 31, 2019 | -88.95% |
| Dec 31, 2018 | 12.36% |